ALNOX Stock Overview
NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany.
NOXXON Pharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€0.12|
|52 Week High||€0.52|
|52 Week Low||€0.061|
|1 Month Change||32.60%|
|3 Month Change||-36.17%|
|1 Year Change||-71.77%|
|3 Year Change||-84.21%|
|5 Year Change||-99.30%|
|Change since IPO||-99.44%|
Recent News & Updates
|ALNOX||FR Biotechs||FR Market|
Return vs Industry: ALNOX underperformed the French Biotechs industry which returned -39.4% over the past year.
Return vs Market: ALNOX underperformed the French Market which returned -3.7% over the past year.
|ALNOX Average Weekly Movement||23.2%|
|Biotechs Industry Average Movement||8.8%|
|Market Average Movement||5.9%|
|10% most volatile stocks in FR Market||9.8%|
|10% least volatile stocks in FR Market||3.4%|
Stable Share Price: ALNOX is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 23% a week.
Volatility Over Time: ALNOX's weekly volatility has increased from 15% to 23% over the past year.
About the Company
NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy.
NOXXON Pharma Fundamentals Summary
|ALNOX fundamental statistics|
Is ALNOX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALNOX income statement (TTM)|
|Cost of Revenue||€0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.17|
|Net Profit Margin||-43,793.94%|
How did ALNOX perform over the long term?See historical performance and comparison
Is NOXXON Pharma undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ALNOX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ALNOX's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: ALNOX is unprofitable, so we can't compare its Price-To-Earnings Ratio to the European Biotechs industry average.
PE vs Market: ALNOX is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALNOX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALNOX is good value based on its Price-To-Book Ratio (2.2x) compared to the FR Biotechs industry average (2.8x).
How is NOXXON Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if ALNOX's forecast earnings growth is above the savings rate (0.3%).
Earnings vs Market: Insufficient data to determine if ALNOX's earnings are forecast to grow faster than the French market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ALNOX's revenue (123.4% per year) is forecast to grow faster than the French market (5.8% per year).
High Growth Revenue: ALNOX's revenue (123.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALNOX's Return on Equity is forecast to be high in 3 years time
How has NOXXON Pharma performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALNOX is currently unprofitable.
Growing Profit Margin: ALNOX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALNOX is unprofitable, and losses have increased over the past 5 years at a rate of 10.2% per year.
Accelerating Growth: Unable to compare ALNOX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALNOX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: ALNOX has a negative Return on Equity (-321.04%), as it is currently unprofitable.
How is NOXXON Pharma's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ALNOX's short term assets (€9.7M) exceed its short term liabilities (€5.3M).
Long Term Liabilities: ALNOX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: ALNOX has more cash than its total debt.
Reducing Debt: ALNOX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALNOX has sufficient cash runway for 9 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: ALNOX is forecast to have sufficient cash runway for 7 months based on free cash flow estimates, but has since raised additional capital.
What is NOXXON Pharma current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALNOX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALNOX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALNOX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALNOX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALNOX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Aram Mangasarian (51 yo)
Dr. Aram Mangasarian, PhD, has been the Chief Executive Officer and Member of Executive Board at NOXXON Pharma N.V. (formerly known as NOXXON Pharma AG) since July 1, 2015 and served as its has been Chief...
CEO Compensation Analysis
Compensation vs Market: Aram's total compensation ($USD627.67K) is above average for companies of similar size in the French market ($USD285.89K).
Compensation vs Earnings: Aram's compensation has increased whilst the company is unprofitable.
Experienced Management: ALNOX's management team is seasoned and experienced (5 years average tenure).
Experienced Board: ALNOX's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.7%.
NOXXON Pharma N.V.'s employee growth, exchange listings and data sources
- Name: NOXXON Pharma N.V.
- Ticker: ALNOX
- Exchange: ENXTPA
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €10.106m
- Shares outstanding: 84.22m
- Website: https://www.noxxon.com
Number of Employees
- NOXXON Pharma N.V.
- Max-Dohrn-Strasse 8-10
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/28 00:00|
|End of Day Share Price||2022/05/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.